# Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

> **NCT04314089** · PHASE1 · COMPLETED · sponsor: **Edward Patz** · enrollment: 31 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** GT103

## Key facts

- **NCT ID:** NCT04314089
- **Lead sponsor:** Edward Patz
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-09
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-12-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314089, "Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04314089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*